The Patent Finder

AIC316 GmbH

12 patents currently held · Updated Nov 17, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jul 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 1, 2027
    The maintenance fee for Crystalline N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)PHENYL]ACETAMIDE Mono Mesylate Monohydrate Having a Specific Particle Size Distribution Range and a Specific Surface Area Range for Use in Pharmaceutical Formulations (US 9,119,786) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,784,887Pharmaceutical preparation of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,119,786Crystalline N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)PHENYL]ACETAMIDE Mono Mesylate Monohydrate Having a Specific Particle Size Distribution Range and a Specific Surface Area Range for Use in Pharmaceutical Formulations
In force
 · High confidence
In forceHigh confidence
US 9,340,535N-[5-(Aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,592,225Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations
In force
 · From the USPTO record
In forceFrom the USPTO record
US RE49,697Crystalline N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N- METHYL-2-[4-(2-Pyridinyl)PHENYL]ACETAMIDE Mono Mesylate Monohydrate Having a Specific Particle Size Distribution Range and a Specific Surface Area Range for Use in Pharmaceutical Formulations
In force
 · Low confidence
In forceLow confidence
US 9,889,124Crystalline N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)PHENYL]ACETAMIDE Mono Mesylate Monohydrate Having a Specific Particle Size Distribution Range and a Specific Surface Area Range for Use in Pharmaceutical Formulations
In force
 · Medium confidence
In forceMedium confidence
US 11,021,474N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,266,636A Maleate Salt of the Free Base of N-[5-(AMINOSULFONYL)-4-Methyl-1.3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)-PHENYL]-ACETAMIDE, Pharmaceutical Formulations, Methods of Manufacture and Uses Thereof for the Treatment of Herpes Viruses
In force
 · High confidence
In forceHigh confidence
US 12,070,451Sulfate Salt of the Free Base of N-[5-(AMINOSULFONYL)-4-Methyl-1,3-Thiazol-2-YL]-N-METHYL-2-[4-(2-Pyridinyl)-PHENYL]-ACETAMIDE, Pharmaceutical Formulations, Methods of Manufacture and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,213,516Intravaginally applicable devices comprising antiviral compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 1 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited